Drug Safety

, Volume 22, Issue 4, pp 263–302 | Cite as

Cardiotoxicity of Chemotherapeutic Agents

Incidence, Treatment and Prevention
Review Article


Cytostatic antibiotics of the anthracycline class are the best known of the chemotherapeutic agents that cause cardiotoxicity. Alkylating agents such as cyclophosphamide, ifosfamide, cisplatin, carmustine, busulfan, chlormethine and mitomycin have also been associated with cardiotoxicity. Other agents that may induce a cardiac event include paclitaxel, etoposide, teniposide, the vinca alkaloids, fluorouracil, cytarabine, amsacrine, cladribine, asparaginase, tretinoin and pentostatin. Cardiotoxicity is rare with some agents, but may occur in >20% of patients treated with doxorubicin, daunorubicin or fluorouracil.

Cardiac events may include mild blood pressure changes, thrombosis, electrocardiographic changes, arrhythmias, myocarditis, pericarditis, myocardial infarction, cardiomyopathy, cardiac failure (left ventricular failure) and congestive heart failure. These may occur during or shortly after treatment, within days or weeks after treatment, or may not be apparent until months, and sometimes years, after completion of chemotherapy.

Anumber of risk factors may predispose a patient to cardiotoxicity. These are: cumulative dose (anthracyclines, mitomycin); total dose administered during a day or a course (cyclophosphamide, ifosfamide, carmustine, fluorouracil, cytarabine); rate of administration (anthracyclines, fluorouracil); schedule of administration (anthracyclines); mediastinal radiation; age; female gender; concurrent administration of cardiotoxic agents; prior anthracycline chemotherapy; history of or pre-existing cardiovascular disorders; and electrolyte imbalances such as hypokalaemia and hypomagnesaemia. The potential for cardiotoxicity should be recognised before therapy is initiated. Patients should be screened for risk factors, and an attempt to modify them should be made.

Monitoring for cardiac events and their treatment will usually depend on the signs and symptoms anticipated and exhibited. Patients may be asymptomatic, with the only manifestation being electrocardiographic changes. Continuous cardiac monitoring, baseline and regular electrocardiographic and echocardiographic studies, radionuclide angiography and measurement of serum electrolytes and cardiac enzymes may be considered in patients with risk factors or those with a history of cardiotoxicity.

Treatment of most cardiac events induced by chemotherapy is symptomatic. Agents that can be used prophylactically are few, although dexrazoxane, a cardioprotective agent specific for anthracycline chemotherapy, has been approved by the US Food and Drug Administration. Cardiotoxicity can be prevented by screening and modifying risk factors, aggressively monitoring for signs and symptoms as chemotherapy is administered, and continuing follow-up after completion of a course or the entire treatment. Prompt measures such as discontinuation or modification of chemotherapy or use of appropriate drug therapy should be initiated on the basis of changes in monitoring parameters before the patient exhibits signs and symptoms of cardiotoxicity.


  1. 1.
    Tan C, Tasaka H, Kou-Ping Y, et al. Daunomycin, an antitumor antibiotic, in the treatment of neoplastic disease: clinical evaluation with special reference to childhood leukemia. Cancer 1967; 20: 333–53PubMedGoogle Scholar
  2. 2.
    Blum RH, Carter SK. Adriamycin: a new anticancer drug with significant clinical activity. Ann Intern Med 1974; 80: 249–59PubMedGoogle Scholar
  3. 3.
    McCredie KB, Hewlett JS, Kennedy A. Sequential Adriamycin-Ara-C (A-OAP) for remission induction (RI) of adult acute leukemia (AAL). Proc Am Assoc Cancer Res 1976; 17: 239Google Scholar
  4. 4.
    Schein PS, DeVita Jr VT, Hubbard S, et al. Bleomycin, adriamycin, cyclophosphamide, vincristine and prednisone (BACOP): combination chemotherapy in the treatment of advanced diffuse histiocytic lymphoma. Ann Intern Med 1976; 85: 417–22PubMedGoogle Scholar
  5. 5.
    Bonnadonna G, DeLena M, Oslenghi C, et al. Combination chemotherapy of advanced Hodgkins disease (HD) with a combination of Adriamycin (ADM), bleomycin (BLM), vinblastine (VBL), and imidazole carboxamide (DTIC) versus MOPP. Proc Am Assoc Cancer Res 1974; 360: 90Google Scholar
  6. 6.
    Cortes EP, Holland JF, Wany JJ, et al. Amputation and adriamycin in primary osteosarcoma.N Engl J Med 1974; 291: 998–1000PubMedGoogle Scholar
  7. 7.
    Cortes EP, Holland JF, Glidwell O. Amputation and adriamycin in primary osteosarcoma. A 5-year report. Cancer Treat Rep 1978; 62: 271–7PubMedGoogle Scholar
  8. 8.
    O’Bryan RM, Luce JK, Talley RW. Phase II evaluation of adriamycin in human neoplasia. Cancer 1973; 32: 1–8PubMedGoogle Scholar
  9. 9.
    Salmon SE, Jones SE. Chemotherapy of advanced breast cancer with adriamycin and cyclophosphamide. Proc Am Assoc Cancer Res 1974; 15: 90Google Scholar
  10. 10.
    Hortobagyi GM, Gutterman JU, Blumenschein GR, et al. Combination chemoimmunotherapy of metastatic breast cancer. Cancer 1979; 44: 1955–62PubMedGoogle Scholar
  11. 11.
    Lippman M, Zager R, Henderson ES. High dose daunorubicin (NSC-83142) in the treatment of advanced acute myelogenous leukemia. Cancer Chemother Rep 1972; 56: 755–60PubMedGoogle Scholar
  12. 12.
    Matthews RN, Colebatch JH. Daunorubicin: results in childhood leukemia. Arch Dis Child 1972; 47: 272–7PubMedGoogle Scholar
  13. 13.
    Sallan SE, Camitta B, Cassady JR, et al. Intermittent combination chemotherapy with Adriamycin for childhood acute lymphoblastic leukemia: clinical results. Blood 1978; 51: 425–33PubMedGoogle Scholar
  14. 14.
    Jones B, Holland JF, Morrison AR, et al. Daunorubicin (NSC-82151) in the treatment of advanced childhood lymphoblastic leukemia. Cancer Res 1971; 31: 84–90PubMedGoogle Scholar
  15. 15.
    Holton CP, Vietti TJ, Nora AH, et al. Clinical study of daunomycin and prednisone for induction of remission in children with advanced leukemia. N Engl J Med 1969; 280: 171–4PubMedGoogle Scholar
  16. 16.
    Hitchcock-Bryan S, Gelber RD, Cassady JR, et al. The impact of induction anthracyclines on long-term failure-free survival in childhood acute lymphoblastic leukemia. Med Pediatr Oncol 1986; 14: 211–5PubMedGoogle Scholar
  17. 17.
    Ettinghausen SE, Bonow RO, Palmeri ST, et al. Prospective study of cardiomyopathy induced by adjuvant doxorubicin therapy in patients with soft-tissue sarcomas. Arch Surg 1986; 121: 1445–51PubMedGoogle Scholar
  18. 18.
    Steinberg JS, Cohen AJ, Wasserman AJ, et al. Acute arrhythmogenicity of doxorubicin administration. Cancer 1987; 60: 1213–8PubMedGoogle Scholar
  19. 19.
    Lenaz L, Page JA. Cardiotoxicity of adriamycin and related anthracyclines. Cancer Treat Rev 1976; 3: 111–20PubMedGoogle Scholar
  20. 20.
    Ferrans VJ. Overview of cardiac pathology in relation to anthracycline cardiotoxicity. Cancer Treat Rep 1978; 62: 955–61PubMedGoogle Scholar
  21. 21.
    Harrison DT, Sanders LA. Pericarditis in a case of early dau norubicin cardiomyopathy. Ann Intern Med 1976; 85: 339–40PubMedGoogle Scholar
  22. 22.
    Frishman WH, Sung HM, Yee HC, et al. Cardiovascular toxicity with cancer chemotherapy. Curr Probl Cancer 1997; 21: 301–60PubMedGoogle Scholar
  23. 23.
    Von Hoff DD, Rozencweig M, Layard M, et al. Daunomycin induced cardiotoxicity in children and adults. A review of 110 cases. Am J Med 1977; 62: 200–8Google Scholar
  24. 24.
    Bristow MR, Billingham ME, Mason JW, et al. Clinical spectrum of anthracycline antibiotic cardiotoxicity. Cancer Treat Rep 1978; 62: 873–9PubMedGoogle Scholar
  25. 25.
    Friedman MA, Bozdech MJ, Billingham ME, et al. Doxorubicin cardiotoxicity. Serial endomyocardial biopsies and systolic time intervals. JAMA 1978; 240: 1603–6PubMedGoogle Scholar
  26. 26.
    Von Hoff DD, Layard MW, Basa P, et al. Risk factors for doxorubicin-induced congestive heart failure. Ann Intern Med 1979; 91: 710–7Google Scholar
  27. 27.
    Praga C, Bretta G, Vigo PL, et al. Adriamycin cardiotoxicity: a survey of 1273 patients. Cancer Treat Rep 1979; 63: 827–34PubMedGoogle Scholar
  28. 28.
    Lefrak EA, Pitha J, Rosenheim S, et al. Aclinicopathologic analysis of adriamycin cardiotoxicity. Cancer 1973; 32: 302–14PubMedGoogle Scholar
  29. 29.
    Haq MM, Legha SS, Choksi J, et al. Doxorubicin induced congestive heart failure in adults. Cancer 1985; 56: 1361–5PubMedGoogle Scholar
  30. 30.
    Schwartz RG, McKenzie WB, Alexander J, et al. Congestive heart failure and left ventricular dysfunction complicating doxorubicin therapy. Seven year experience using serial radionuclide angiocardiography. Am J Med 1987; 82: 1109–18PubMedGoogle Scholar
  31. 31.
    Steinherz LJ, Steinherz PG, Tan CT, et al. Cardiac toxicity 4 to 20 years after completing anthracycline therapy. JAMA 1991; 266: 1672–7PubMedGoogle Scholar
  32. 32.
    Lipshultz SE, Colan SD, Gelber RD, et al. Late cardiac effects of doxorubicin therapy for acute lymphoblastic leukemia of childhood. N Engl J Med 1991; 324: 808–15PubMedGoogle Scholar
  33. 33.
    Yeung ST, Yoong C, Spink J, et al. Functional myocardial impairment in children treated with anthracyclines for cancer. Lancet 1991; 337: 816–8PubMedGoogle Scholar
  34. 34.
    Larsen RL, Jakacki RI, Vetter VL, et al. Electrocardiographic changes and arrhythmias after cancer therapy in children and young adults. Am J Cardiol 1992; 70: 73–7PubMedGoogle Scholar
  35. 35.
    Steinherz LJ, Steinherz PG, Tan C. Cardiac failure and dysrhythmias 6-19 years after anthracycline therapy: a series of 15 patients. Med Pediatr Oncol 1995; 24: 352–61PubMedGoogle Scholar
  36. 36.
    Steinherz L, Steinherz P. Delayed cardiotoxicity from anthracycline therapy. Pediatrician 1991; 18: 49–52PubMedGoogle Scholar
  37. 37.
    Ali MK, Ewer MS, Gibbs HR, et al. Late doxorubicin associated cardiotoxicity in children. The possible role of intercurrent viral infection. Cancer 1994; 74; 182–8PubMedGoogle Scholar
  38. 38.
    Doroshow JH. Effect of anthracycline antibiotics on oxygen radical formation in rat heart. Cancer Res 1983; 43: 460–72PubMedGoogle Scholar
  39. 39.
    Rajagopalan S, Politi PM, Sinha BK, et al. Adriamycin-induced free radical formation in the perfused rat heart: implications for cardiotoxicity. Cancer Res 1988; 48: 4766–9PubMedGoogle Scholar
  40. 40.
    Jackson JA, Reeves JP, Muntz KH, et al. Evaluation of free radicals effects and catecholamines alterations in adriamycin cardiotoxicity. Am J Med 1984; 117: 140–53Google Scholar
  41. 41.
    Myers CE, McGuire WP, Liss RH, et al. Adriamycin: the role of lipid peroxidation in cardiac toxicity and tumor response. Science 1977; 197: 165–7PubMedGoogle Scholar
  42. 42.
    Unverferth DV, Fertel RH, Balcerzak SP, et al. N-Acetylcysteine prevents the doxorubicin-induced decrease of cyclic GMP. Semin Oncol 1983; 10Suppl. 1: 49–52PubMedGoogle Scholar
  43. 43.
    Mushlin PS, Olson RD. Anthracycline cardiotoxicity: new insights. Ration Drug Ther 1988; 22: 1–8PubMedGoogle Scholar
  44. 44.
    Dorshow JH, Locker GY, Myers CE. Enzymatic defenses of the mouse heart against reactive oxygen metabolites: alterations produced by doxorubicin. J Clin Invest 1980; 65128–35Google Scholar
  45. 45.
    Keizer HG, Pinedo HM, Shuurhuis GJ, et al. Doxorubicin (Adriamycin): a critical review of free radical-dependent mechanisms of cytotoxicity. Pharmacol Ther 1990; 47: 219–31PubMedGoogle Scholar
  46. 46.
    Olson RD, Mushlin PS, Brenner DE, et al. Doxorubicin cardiotoxicity may be caused by its metabolite, doxorubicinol. Proc Natl Acad Sci USA 1988; 85; 3585–9PubMedGoogle Scholar
  47. 47.
    Rhoden W, Hasleton P, Brooks N. Anthracyclines and the heart. Br Heart J 1993; 70: 499–502PubMedGoogle Scholar
  48. 48.
    Waagstein F, Fu LX, Hjalmarson A. A new insight into adriamycin-induced cardiotoxicity. Int J Cardiol 1990; 29: 15–20PubMedGoogle Scholar
  49. 49.
    Ehrke MJ, Maccubbin D, Ryoyoma K, et al. Correlation between adriamycin-induced augmentation of interleukin-2 production and of cell-mediated cytotoxicity in mice. Cancer Res 1986; 46: 54–60PubMedGoogle Scholar
  50. 50.
    Shi F, MacEwen EG, Kurzman ID. In vitro and in vivo effect of doxorubicin combined with liposome encapsulated muramyl tripeptide on canine monocyte activation. Cancer Res 1993; 53: 3986–91PubMedGoogle Scholar
  51. 51.
    Abdul Hamied TA, Parker D, Turk JL. Effects of adriamycin, 4-hydroperoxycyclophosphamide and ASTA Z 7557 (INN mafosfamide) on the release of IL-2 and IL-1 in vitro. Int J Immunopharmacol 1987; 9: 355–61PubMedGoogle Scholar
  52. 52.
    Torre-Amione G, Kapadia S, Lee J, et al. Expression and functional significance of tumor necrosis factor receptors in human myocardium. Circulation 1995; 92: 1487–93PubMedGoogle Scholar
  53. 53.
    Hegewisch S, Weh HJ, Hossfeld DK. TNF-induced cardiomyopathy [letter]. Lancet 1990; 335: 294–5PubMedGoogle Scholar
  54. 54.
    Beck AC, Ward JH, Hammond EH, et al. Cardiomyopathy associated with high-dose interleukin-2 therapy. West J Med 1991; 155: 293–6PubMedGoogle Scholar
  55. 55.
    Robison TW, Giri SN. Effects of chronic administraion of doxorubicin on myocardial β-andrenergic receptors. Life Sci 1986; 39: 731–6PubMedGoogle Scholar
  56. 56.
    Cuthbertson DD, Epstein ST, Lipshultz SE, et al. Anthracycline cardiotoxicity in children with cancer. Circulation 1994; 90Suppl.: 1–50Google Scholar
  57. 57.
    Giantris A, Abdurrahman L, Hinkle A, et al. Anthracycline-induced cardiotoxicity in children and young adults. Crit Rev Oncol Hematol 1998; 27: 53–68PubMedGoogle Scholar
  58. 58.
    Krischer JP, Epstein S, Cuthbertson DD, et al. Clinical cardiotoxicity following anthracycline treatment for childhood cancer: the pediatric oncology group experience. J Clin Oncol 1997; 15: 1544–52PubMedGoogle Scholar
  59. 59.
    Bristow MR, Mason JW, Billingham ME, et al. Doxorubicin cardiomyopathy: evaluation by phonocardiography, endomyocardial biopsy, and cardiac catherization. Ann Intern Med 1978; 88: 168–75PubMedGoogle Scholar
  60. 60.
    Cortes EP, Lutman G, Wanka J, et al. Adriamycin (NSC-123127) cardiotoxicity: aclinicopathologic correlation. Cancer Chemother Rep 1975; 6: 215–25Google Scholar
  61. 61.
    Legha SS, Benjamin RS, Mackay B, et al. Reduction of doxorubicin cardiotoxicity by prolonged continuous intravenous infusion. Ann Intern Med 1982; 96: 133–9PubMedGoogle Scholar
  62. 62.
    Torti FM, Bristow MR, Howes AE, et al. Reduced cardiotoxicity of doxorubicin delivered on a weekly schedule. Assessment by endomyocardial biopsy. Ann Intern Med 1983; 99: 745–9PubMedGoogle Scholar
  63. 63.
    Weiss AJ, Metter GE, Fletcher WS, et al. Studies on Adriamycin using a weekly regimen demonstrating its clinical effectiveness and lack of cardiac toxicity. Cancer Treat Rep 1976; 80: 813–22Google Scholar
  64. 64.
    Weiss AJ, Manthel RW. Experience with the use of Adriamycin in combination with other anticancer agents using a weekly schedule with particular reference to lack of cardiac toxicity. Cancer 1977; 40: 2046–52PubMedGoogle Scholar
  65. 65.
    Chelobowski RT, Paroly WS, Pugh RP, et al. Adriamycin given as a weekly schedule without a loading course: clinically effective with reduced incidence of cardiotoxicity. Cancer Treat Rep 1980; 64: 47–51Google Scholar
  66. 66.
    Lipshultz SE, Rifai N, Sallan SE, et al. Predictive value of cardiac troponin T in pediatric patients at risk for myocardial injury. Circulation 1997; 96: 2641–8PubMedGoogle Scholar
  67. 67.
    Pratt CB, Ransom JL, Evans WE. Age-related adriamycin cardiotoxicity in children. Cancer Treat Rep 1978; 62: 1381–5PubMedGoogle Scholar
  68. 68.
    Dearth J, Osborn R, Wilson E, et al. Anthracycline-induced cardiomyopathy in children: a report of six cases. Med Pediatr Oncol 1984; 12: 54–8PubMedGoogle Scholar
  69. 69.
    Lipshultz SE, Lipsitz SR, Mone SM, et al. Female sex and higher dose as risk factors for late cardiotoxic effects of doxorubicin therapy for childhood cancer. N Engl J Med 1995; 332: 1738–43PubMedGoogle Scholar
  70. 70.
    Silber JH, Javkaki RI, Larsen RL, et al. Increased risk of cardiac dysfunction after anthracyclines in girls. Med Pediatr Oncol 1993; 21: 477–9PubMedGoogle Scholar
  71. 71.
    Pihkala J, Saarinen UM, Lundstrom U, et al. Myocardial function in children and adolescents after therapy with anthracyclines and chest irradiation. Eur J Cancer 1996; 32A: 97–103PubMedGoogle Scholar
  72. 72.
    Dresdale A, Bonow RO, Wesley R, et al. Prospective evaluation of doxorubicin-induced cardiomyopathy resulting from postsurgical adjuvant treatment of patients with soft tissue sarcomas. Cancer 1983; 52: 51–60PubMedGoogle Scholar
  73. 73.
    Gottdiener JS, Appelbaum FR, Ferrans VJ, et al. Cardiotoxicity associated with high dose cyclophosphamide therapy. Arch Intern Med 1981; 141: 758–63PubMedGoogle Scholar
  74. 74.
    Chakko S, Woska D, Martinez H, et al. Clinical, radiographic and hemodynamic correlations in chronic congestive heart failure: conflicting result may lead to inappropriate care. Am J Med 1991; 90: 353–6PubMedGoogle Scholar
  75. 75.
    Mason JW, Bristow MR, Billingham ME, et al. Invasive and non-invasive methods of assessing adriamycin cardiotoxic effects in man: superiority of histopathologic assessment using endomyocardial biopsy. Cancer Treat Rep 1978; 62: 857–64PubMedGoogle Scholar
  76. 76.
    Billingham ME, Bristow MR. Evaluation of anthracycline cardiotoxicity: predictive ability and functional correlation of endomyocardial biopsy. Cancer Treat Symp 1984; 3: 71–6Google Scholar
  77. 77.
    Billingham ME, Mason JW, Bristow MR, et al. Anthracycline cardiomyopathy monitored by morphological changes. Cancer Treat Rep 1978; 62: 865–72PubMedGoogle Scholar
  78. 78.
    Bristow MR, Thompson PD, Martin RP, et al. Early anthracycline cardiotoxicity. Am J Med 1978; 65: 823–32PubMedGoogle Scholar
  79. 79.
    Lipshultz SE, Orav EJ, Sanders SP, et al. Limitations of fractional shortening as an index of contractility in pediatric patients infected with HIV. J Pediatr 1994; 125: 563–70PubMedGoogle Scholar
  80. 80.
    Druck MN, Gulenchyn KY, Evans WK, et al. Radionuclide angiography and endomyocardial biopsy in the assessment of doxorubicin cardiotoxicity. Cancer 1998; 53: 1667–74Google Scholar
  81. 81.
    Ganz WI, Sridhar KS, Ganz SS, et al. Review of tests for monitoring doxorubicin-induced cardiomyopathy. Oncology 1996; 53: 461–70PubMedGoogle Scholar
  82. 82.
    Bristow MR, Mason JW, Billingham MW, et al. Dose-effect and structure-function relationships in doxorubicin cardiomyopathy. Am Heart J 1981; 102: 709–18PubMedGoogle Scholar
  83. 83.
    Dorr RT, Von Hoff DD. Cancer chemotherapy handbook. 2nd edition. Connecticut: Appleton and Lange, 1994Google Scholar
  84. 84.
    Thomas C, Vile GF, Winterbourn CC. The hydrolysis product of ICRF-187 promotes iron-catalysed hydroxyl radical production via the Fenton reaction. Biochem Pharmacol 1993; 45: 1967–72PubMedGoogle Scholar
  85. 85.
    Williams GA, Johnson JR, Burke G. FDA oncology drugs advisory committee review of Zinecard (dexrazoxane, ADR-529, ICRF-187). Rockville(MD): Center for Drug Evaluation and Research, US Food and Drug Administration, 1992: 1–13Google Scholar
  86. 86.
    Speyer JL, Green MD, Zeleniuch-Jacquotte A, et al. ICRF-187 permits longer treatment with doxorubicin in women with breast cancer. J Clin Oncol 1992; 10: 117–27PubMedGoogle Scholar
  87. 87.
    Wexler LH, Andrich MP, Venzon D, et al. Randomized trial of the cardioprotective agent ICRF-187 in pediatric sarcoma patients treated with doxorubicin. J Clin Oncol 1996; 14: 362–72PubMedGoogle Scholar
  88. 88.
    Venturini M, Michelotti A, Del Mastro L, et al. Multicenter randomized controlled clinical trial to evaluate cardioprotection of dexrazoxane versus no cardioprotection in women receiving epirubicin chemotherapy for advanced breast cancer. J Clin Oncol 1996; 14: 3112–20PubMedGoogle Scholar
  89. 89.
    Siveski-Iliskovic N, Kaul N, Singal PK. Probucol promotes endogenous antioxidant and provides protection against Adriamycin-induced cardiomyopathy in rats. Circulation 1994; 89: 29–35Google Scholar
  90. 90.
    Siveski-Iliskovic N, Hill M, Chow DA, et al. Probucol protects against Adriamycin cardiomyopathy without interfering with its anti-tumor effect. Circulation 1995; 91: 10–5PubMedGoogle Scholar
  91. 91.
    Singal PK, Siveski-Iliskovic N, Hill M, et al. Combination therapy with probucol prevents Adriamycin-induced cardiomyopathy. J Mol Cell Cardiol 1995; 27: 1055–63PubMedGoogle Scholar
  92. 92.
    Decorti G, Klugmann FB, Candussio L. Characterization of histamine secretion induced anthracyclines in rat peritoneal mast cells. Biochem Pharmacol 1986; 35: 1939–41PubMedGoogle Scholar
  93. 93.
    Klugmann FB, Decorti G, Candussio L. Amelioration of 4-epidoxorubicin induced cardiotoxicity by sodium cromoglycate. Eur J Cancer Clin Oncol 1989; 25: 361–8PubMedGoogle Scholar
  94. 94.
    deJong J, Schoofs PR, Onderwater RC, et al. Isolated mouse atrium as a model to study anthracycline cardiotoxicity: the role of beta-adrenoreceptor system and reactive oxygen species. Res Commun Chem Pathol Pharmacol 1990; 68: 275–89Google Scholar
  95. 95.
    Rasmussen IMN, Schou HS, Hermansen K. Cardiotoxic effects and the influence on the Padrenoreceptor function of doxorubicin (adriamycin) in the rat. Pharmacol Toxicol 1989; 65: 69–72PubMedGoogle Scholar
  96. 96.
    Plosker GL, Faulds D, Epirubicin. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in cancer chemotherapy. Drugs 1993; 45(5): 788–856PubMedGoogle Scholar
  97. 97.
    Ganzina F. 4-epi-doxorubicin, a new analogue of doxorubicin: a preliminary overview of preclinical and clinical data. Cancer Treat Rev 1983; 10: 1–22PubMedGoogle Scholar
  98. 98.
    Cersosimo RJ, Hong Wk. Epirubicin — a review of the pharmacology, clinical activity and adverse effects of an Adriamycin analogue. J Clin Oncol 1986; 4: 425–39PubMedGoogle Scholar
  99. 99.
    Brambilla C, Rossi A, Bonfante V, et al. Phase II study of doxorubicin versus epirubicin in advanced breast cancer. Cancer Treat Rep 1986; 70: 261–6PubMedGoogle Scholar
  100. 100.
    Jain KK, Casper ES, Geller NL, et al. Aprospective randomized comparison of epirubicin and doxorubicin in patients with advanced breast cancer. J Clin Oncol 1985; 3: 818–26PubMedGoogle Scholar
  101. 101.
    Intini C, Sacchetti G. FEC vs FAC in advanced breast cancer. An Italian multicenter trial. In: Ishigami J, editor. Recent advances in chemotherapy. Tokyo, Japan: University of Tokyo Press, 1986; 1198–9Google Scholar
  102. 102.
    Torti FM, Bristow MR, Lum BL, et al. Cardiotoxicity of epirubicin and doxorubicin: assessment by endomyocardial biopsy. Cancer Res 1986; 46: 3722–7PubMedGoogle Scholar
  103. 103.
    Mengozzi G, Palagi C, Petronio AS, et al. The evaluation of cardiotoxicity of 4 epidoxorubicin at high doses. Cardiologia 1991; 36: 137–42PubMedGoogle Scholar
  104. 104.
    Lahtinen R, Kuikka J, Nousiainen T, et al. Cardiotoxicity of epirubicin and doxorubicin: a double blind randomized study. Eur J Haematol 1991; 46: 301–5PubMedGoogle Scholar
  105. 105.
    Anderlini P, Benjamin RS, Wong FC, et al. Idarubicin cardiotoxicity: a retrospective study in acute myeloid leukemia and myelodysplasia. J Clin Oncol 1995; 13: 2827–34PubMedGoogle Scholar
  106. 106.
    Penco S, Casazza AM, Franchi G, et al. Synthesis, antitumor activity and cardiac toxicity of new 4 demethoxy-anthracyclines. Cancer Treat Rev 1983; 67: 665–73Google Scholar
  107. 107.
    Anon. Consensus recommendations for the management of chronic heart failure. On behalf of the membership of the Advisory Council to Improve Outcomes Nationwide in Heart Failure. Am J Cardiol 1999; 83: 1A–38AGoogle Scholar
  108. 108.
    Arlin ZA, Silver R, Cassileth P, et al. Phase I-II trial of mitoxantrone in acute leukemia. Cancer Treat Rep 1985; 69: 61–4PubMedGoogle Scholar
  109. 109.
    Paiucci PA, Ohnuma T, Cuttner J, et al. Mitoxantrone in patients with acute leukemia in relapse. Cancer Res 1983; 43: 3919–22Google Scholar
  110. 110.
    Henderson BM, Dougherty WJ, James VC, et al. Safety assessment of a new anticancer compound, mitoxantrone, in beagle dogs: comparison with doxorubicin. I. Clinical observations. Cancer Treat Rep 1982; 66: 1139–43PubMedGoogle Scholar
  111. 111.
    Sparano BM, Gondon G, Hall C, et al. Safety assessment of a new anticancer compound, mitoxantrone, in beagle dogs: comparison with doxorubicin. II. Histologic and ultrastructural pathology. Cancer Treat Rep 1982; 66: 1145–58PubMedGoogle Scholar
  112. 112.
    Von Hoff DD, Pollard E, Kuhn J, et al. Phase I clinical investigation of 1,4-dihydroxy-5,8-bis (((2-((2-hydroxythyl)-amino(ethyl(amino))-9, 10-anthracenedione dihydrochloride (NSC 301739), a new anthracenedione. Cancer Res 1980; 40: 1516–8Google Scholar
  113. 113.
    Schell FC, Yap H-Y, Blumenschein G, et al. Potential cardiotoxicity with mitoxantrone. Cancer Treat Rep 1982; 66: 1641–3PubMedGoogle Scholar
  114. 114.
    Pratt CB, Crom DB, Wallenbert J, et al. Fatal congestive heart failure following mitoxantrone treatment in two children previously treated with doxorubicin and cisplatin. Cancer Treat Rep 1983; 67: 85–8PubMedGoogle Scholar
  115. 115.
    Unverferth DV, Unverferth BJ, Balcerzak, et al. Cardiac evaluation of mitoxantrone. Cancer Treat Rep 1983; 67: 343–50PubMedGoogle Scholar
  116. 116.
    Stuart-Harris R, Pearson M, Smith IE. Cardiotoxicity associated with mitoxantrone. Lancet 1984; 2: 219–20PubMedGoogle Scholar
  117. 117.
    Coleman RE, Maisey MN, Knight RK, et al. Mitoxantrone in advanced breast cancer: a phase II study with special attention to cardiotoxicity. Eur J Cancer Clin Oncol 1984; 20: 771–6PubMedGoogle Scholar
  118. 118.
    Smith IE. Mitoxantrone (novantrone): a review of experimental and early clinical studies. Cancer Treat Rev 1983; 10: 103–15PubMedGoogle Scholar
  119. 119.
    Clark GM, Tokaz LK, Von Hoff DD, et al. Cardiotoxicity in patients treated with mitoxantrone on Southwest Oncology Group phase II protocols. Cancer Treat Symp 1984; 3: 25–30Google Scholar
  120. 120.
    Mather FJ, Simon RM, Clark GM, et al. Cardiotoxicity in patients treated with mitoxantrone: Southwest Oncology Group Phase II studies. Cancer Treat Rep 1987; 71: 609–13PubMedGoogle Scholar
  121. 121.
    Ungerleider RS, Pratt CB, Vietti TJ, et al. Phase I trial of mitoxantrone in children. Cancer Treat Rep 1985; 69: 403–7PubMedGoogle Scholar
  122. 122.
    Posner LE, Dukart G, Goldberg J, et al. Mitoxantrone: an over view of safety and toxicity. Invest New Drugs 1985; 3: 123–32PubMedGoogle Scholar
  123. 123.
    Stewart DJ, Green RM, Mikhael NZ, et al. Human autopsy tissue concentration of mitoxantrone. Cancer Treat Rep 1986; 70: 1255–61PubMedGoogle Scholar
  124. 124.
    Novak RF, Kharasch ED. Mitoxantrone: propensity for free radical formation and lipid peroxidation implications for cardiotoxicity. Invest New Drugs 1985; 3: 95–9PubMedGoogle Scholar
  125. 125.
    Simson MB, Untereker WJ, Spielman SR, et al. Relation between late potentials on the body surface and directly recorded fragmented electrograms in patients with ventricular tachycardia. Am J Cardiol 1983; 57: 105–12Google Scholar
  126. 126.
    Gomes JA, Mehra R, Barreca P, et al. A comparative analysis of signal averaging of the surface QRS complex and intercardiac and epicardiac recordings of ventricular tachycardia: a review. Clin Cardiol 1989; 12: 307–12Google Scholar
  127. 127.
    Emergency Cardiac Care Committee and Subcommittees, American Heart Association. Guidelines for cardiopulmonary resuscitation and emergency cardiac care III: Adult advanced cardiac life support. JAMA 1992; 268: 2199–241Google Scholar
  128. 128.
    Ryan TJ, Anderson JL, Antman EM, et al. ACC/AHA guidelines for the management of patients with accute myocardial infarction: a report of the American College of Cardiology/American Heart Association Task Force on Practical Guidelines (committe on Management of Acute Myocardial Infarction). J Am Coll Cardiol 1996; 28: 1328–428PubMedGoogle Scholar
  129. 129.
    Teicher BA. Antitumor alkylating agent. In: DeVita Jr VT, Hellman S, Rosenberg SA, editors. Cancer: principles and practice of oncology. Philadelphia: Lippincott-Raven, 1997: 405-18Google Scholar
  130. 130.
    DeVita VT, Serpick AA, Carbone PP. Combination chemotherapy in the treatment of advanced Hodgkins disease. Ann Intern Med 1970; 73: 881–95PubMedGoogle Scholar
  131. 131.
    Alexanian R, Salmon S, Bonnet J. Combination therapy for multiple myeloma. Cancer 1977; 40: 2765–71PubMedGoogle Scholar
  132. 132.
    Skarin AT, Rosenthal DS, Moloney WC, et al. Combination chemotherapy of advanced non-Hodgkins lymphoma with bleomycin, Adriamycin, cyclophosphamide, vincristine and prednisone (BACOP). Blood 1977; 29: 759–70Google Scholar
  133. 133.
    Muggia FM, Chia G, Reed LJ, et al. Doxorubicin-cyclophosphamide: effective chemotherapy for advanced endometrial adenocarcinoma. Am J Obstet Gynecol 1977; 128: 314–9PubMedGoogle Scholar
  134. 134.
    Livingston RB, Moore TW, Heilburn L. Small cell carcinoma of the lung combined chemotherapy and radiation. Ann Intern Med 1978; 88: 194–9PubMedGoogle Scholar
  135. 135.
    Armitage JO, Antman KH, editors. High dose therapy: pharmacology, hematopoietins, stem cells. Baltimore: Williams and Wilkins, 1995Google Scholar
  136. 136.
    Eder JP, Antman K, Peters W, et al. High-dose combination of alkylating agent chemotherapy with autologous bone marrow support for metastatic breast cancer. J Clin Oncol 1986; 4: 1592–7PubMedGoogle Scholar
  137. 137.
    Dow E, Schulman H, Agura E. Cyclophosphamide cardiac injury mimicking acute myocardial infarction. Bone Marrow Transplant 1993; 12: 169–72PubMedGoogle Scholar
  138. 138.
    Appelbaum F, Strauchen JA, Graw Jr RG, et al. Acute lethal carditis caused by high-dose combination chemotherapy. A unique clinical and pathological entity. Lancet 1976; I: 58–62Google Scholar
  139. 139.
    Goldberg MA, Antin JH, Guinan EC, et al. Cyclophosphamide cardiotoxicity: an analysis of dosing as a risk factor. Blood 1986; 68: 1114–8PubMedGoogle Scholar
  140. 140.
    Buja LM, Ferrans VJ, Graw Jr RG. Cardiac pathologic findings in patients treated with bone marrow transplantation. Human Pathol 1976; 7: 17–45Google Scholar
  141. 141.
    Cazin B, Gorin NC, Laporte JP, et al. Cardiac complications after bone marrow transplantation. A report on a series of 63 consecutive transplantations. Cancer 1986; 57: 2061–9PubMedGoogle Scholar
  142. 142.
    Steinherz LJ, Steinherz PG, Mangiacasale D, et al. Cardiac changes with cyclophosphamide. Med Pediatr Oncol 1981; 9: 417–22PubMedGoogle Scholar
  143. 143.
    Kupari M, Volin L, Suokas A, et al. Cardiac involvement in bone marrow transplantation: electrocardiographic changes, arrhythmias, heart failure and autopsy findings. Bone Marrow Transplant 1990; 5: 91–8PubMedGoogle Scholar
  144. 144.
    Buckner CD, Rudolph RH, Fefer A, et al. High-dose cyclophosphamide therapy for malignant disease. Toxicity, tumor response and the effects of stored autologous marrow. Cancer 1972; 29: 357–65Google Scholar
  145. 145.
    Gardner SF, Lazarus HM, Bednarczyk EM, et al. High-dose cyclophosphamide-induced myocardial damage during BMT: assessment by positron emission tomography. Bone Marrow Transplant 1993; 12: 139–44PubMedGoogle Scholar
  146. 146.
    Braverman AC, Antin JH, Plappert MT, et al. Cyclophosphamide cardiotoxicity in bone marrow transplantation: a prospective evaluation of new dosing regimens. J Clin Oncol 1991; 9: 1215–23PubMedGoogle Scholar
  147. 147.
    Ayash LJ, Wright JE, Tretyakov O, et al. Cyclophosphamide pharmacokinetics: correlation with cardiac toxicity and tumor response. J Clin Oncol 1992; 10: 995–1000PubMedGoogle Scholar
  148. 148.
    Antman KH, Montella D, Rosenbaum C. Phase II trial of ifosfamide with MESNA in previously treated metastatic sarcoma. Cancer Treat Rep 1985; 69: 499–504PubMedGoogle Scholar
  149. 149.
    Bramwell VHC, Mouridsen HT, Santoro A. Cyclophosphamide versus ifosfamide: final report of a randomized phase II trial in adult soft tissue sarcomas. Eur J Cancer Clin Oncol 1987; 23: 311–21PubMedGoogle Scholar
  150. 150.
    Costanzi JJ, Morgan LR, Hokanson J. Ifosfamide in the treatment of extensive non-oat cell carcinoma of the lung. Semin Oncol 1982; 9: 61–5PubMedGoogle Scholar
  151. 151.
    Zenaide MNQ, Wilson WH, Cunnion RE, et al. High-dose ifosfamide is associated with severe, reversible cardiac dysfunction. Ann Intern Med 1993; 118: 31–6Google Scholar
  152. 152.
    Davies SM, Pearson AD, Craft AW. Toxicity of high-dose ifosfamide in children. Cancer Chemother Pharmacol 1989; 24Suppl.: S8–10PubMedGoogle Scholar
  153. 153.
    Skinner R, Pearson AD, Price L, et al. Nephrotoxicity after ifosfamide. Arch Dis Child 1990; 65: 732–8PubMedGoogle Scholar
  154. 154.
    Zales VR, Wright KL. Endocarditis, pericarditis, and myocarditis. Pediatr Ann 1997; 26: 116–21PubMedGoogle Scholar
  155. 155.
    O’Dwyer PJ, Johnson SW, Hamilton TC. Cisplatin and its analogues. In: DeVita Jr VT, Hellman S, Rosenberg SA, editors. Cancer: principles and practice of oncology. Philadelphia: Lippincott-Raven, 1997: 418–32Google Scholar
  156. 156.
    Talley RW, O Bryan RM, Gutterman JU, et al. Clinical evaluation of toxic effects of cis-diammine dichloroplatinum (NSC-119875): Phase I clinical study. Cancer Chemother Rep 1973; 57: 465–71PubMedGoogle Scholar
  157. 157.
    Wiltshaw E, Carr B. Cis-platinum (II) diamminedichloride: clinical experience of the Royal Marsden Hospital and Institute of Cancer Research. In: Connors, Roberts, editors. Platinum coordination complexes in cancer chemotherapy. London: Springer, 1974: 178–82Google Scholar
  158. 158.
    Licciardello JT, Moake JL, Rudy CK, et al. Elevated plasma von Willebrand factor levels and arterial occlusive complications associated with cisplatin-based chemotherapy. Oncology 1985; 42: 296–300PubMedGoogle Scholar
  159. 159.
    Goldhirsch A, Joss R, Markwalder TM, et al. Acute cerebrovascular accident after treatment with cis-platinum and methylprednisolone. Oncology 1983; 40: 344–5PubMedGoogle Scholar
  160. 160.
    Hashimi LA, Khalyl MF, Salem PA. Supraventricular tachycardia a probable complication of platinum treatment. Oncology 1984; 41: 174–5PubMedGoogle Scholar
  161. 161.
    Shaeppi U, Heyman IA, Fleschman RW. Cis-diamminedichloroplatinum (II) preclinical evaluation of intravenous injection in dogs, monkeys and mice. Toxicol Appl Pharmacol 1973; 25: 230Google Scholar
  162. 162.
    Canobbio L, Fassio T, Gasparini G, et al. Cardiac arrhythmia: possible complication from treatment with cisplatin. Tumori 1986; 72: 201–4PubMedGoogle Scholar
  163. 163.
    Doll DC, List AF, Greco A, et al. Acute vascular ischemic events after cisplatin-based combination chemotherapy for germ-cell tumors of the testis. Ann Intern Med 1986; 105: 48–51PubMedGoogle Scholar
  164. 164.
    Talcott JA, Herman TS. Acute ischemic vascular events and cisplatin. Ann Intern Med 1987; 107(1): 121–2PubMedGoogle Scholar
  165. 165.
    Berliner S, Rahima M, Sidi Y, et al. Acute coronary events following cisplatin-based chemotherapy. Cancer Invest 1990; 8: 583–6PubMedGoogle Scholar
  166. 166.
    Bodensteiner DC. Fatal coronary artery fibrosis after treatment with bleomycin, vinblastine and cis-platinum. South Med J 1981; 74: 898–9PubMedGoogle Scholar
  167. 167.
    Jackson AM, Rose BD, Graff LG, et al. Thrombotic microangiopathy and renal failure associated with antineoplastic chemotherapy. Ann Intern Med 1987; 101: 121–2Google Scholar
  168. 168.
    Vogelzang NJ, Torkelson JL, Kennedy BJ. Hypomagnesemia, renal dysfunction and Raynaud’s phenomenon in patients treated with cisplatin, vinblastine and bleomycin. Cancer 1985; 56: 2765–70PubMedGoogle Scholar
  169. 169.
    Rosenfeld CS, Broder LE. Cisplatin-induced autonomic neuropathy. Cancer Treat Rep 1984; 68; 659–60PubMedGoogle Scholar
  170. 170.
    Turlapaty PD, Altura BM. Magnesium deficiency produces spasms of coronary arteries: relationship to etiology of sudden death ischemic heart disease. Science 1980; 208: 198–200PubMedGoogle Scholar
  171. 171.
    Altura BM, Altura BT, Gebrewold A, et al. Magnesium deficiency and hypertension: correlation between magnesium deficient diets and microcirculatory changes in situ. Science 1984; 223: 1315–7PubMedGoogle Scholar
  172. 172.
    Crooke ST, Bradner WT. Mitomycin C: a review. Cancer Treat Rep 1976; 3: 121–9Google Scholar
  173. 173.
    Tomasz M. H2O2 generation during the redox cycle of mitomycin C and DNA-bound mitomycin C. Chem Biol Interact 1976; 13: 89–97PubMedGoogle Scholar
  174. 174.
    Tomasz M, Chowdary D, Lipman R. Reaction of DNA with chemically or enzymatically activated mitomycin C: isolation and structure of major covalent adduct. Proc Natl Acad Sci USA 1986; 83: 6702–6PubMedGoogle Scholar
  175. 175.
    Lenaz L. Mitomycin C in advanced breast cancer. Cancer Treat Rev 1985; 23: 235–49Google Scholar
  176. 176.
    Wise GR, Kuhn IN, Godfrey TE. Mitomycin C in large infrequent dosages in breast cancer. Med Pediatr Oncol 1976; 2: 55–60PubMedGoogle Scholar
  177. 177.
    Miller TP, McMohan LJ, Livingston RB. Extensive adenocarcinoma and large cell undifferentiated carcinoma of the lung treated with 5-FU, vincristine and mitomycin C (FOMI). Cancer Treat Rep 1980; 64: 1241–5PubMedGoogle Scholar
  178. 178.
    Liu K, Mittelman A, Sproul EE, et al. Renal toxicity in man treated with mitomycin C. Cancer 1971; 28: 1314–20PubMedGoogle Scholar
  179. 179.
    Orwoll ES, Kiessling PJ, Patterson JR. Interstitial pneumonia from mitomycin. Ann Intern Med 1978; 89: 352–5PubMedGoogle Scholar
  180. 180.
    Suzuki Y, Nube H. Radiation-induced heart injury: Radio-pathological study. Kita Kanto Igaku 1975; 25: 395–407Google Scholar
  181. 181.
    Verweij J, van der Burg MEL, Pinedo HM. Mitomycin C-induced hemolytic uremic syndrome. Six case reports and review of the literature on renal, pulmonary and cardiac side effects of the drug. Radiother Oncol 1987; 8: 33–41PubMedGoogle Scholar
  182. 182.
    Buzdar AU, Legha SW, Tashima CK, et al. Adriamycin and mitomycin C: possible synergistic cardiotoxicity. Cancer Treat Rep 1978; 62: 1005–8PubMedGoogle Scholar
  183. 183.
    Creech RH, Catalano RB, Shah MK, et al. An effective low-dose mitomycin regimen for hormonal- and chemotherapy-refractory patients with metastatic breast cancer. Cancer 1983; 51: 1034–40PubMedGoogle Scholar
  184. 184.
    Doyle LA, Ihde DC, Carney DN, et al. Combination chemotherapy with doxorubicin and mitomycin C in non-small cell bronchogenic carcinoma. Am J Clin Oncol 1984; 7: 719–24PubMedGoogle Scholar
  185. 185.
    Villani F, Comazzi R, Lacaita G, et al. Possible enhancement of the cardiotoxicity of doxorubicin when combined with mitomycin C. Med Oncol Tumor Pharmacother 1985; 2: 93–7Google Scholar
  186. 186.
    Verweij J, Funke-Kupper AJ, Teule GJ, et al. A prospective study on the dose dependency of cardiotoxicity induced by mitomycin C. Med Oncol Tumor Pharmacother 1988; 5: 159–63PubMedGoogle Scholar
  187. 187.
    Tomasz M, Mercado CM, Olson J, et al. The mode of interaction of mitomycin C with deoxyribonucleic acid and other polynucleotides in vitro. Biochemistry 1974; 13: 4878–87PubMedGoogle Scholar
  188. 188.
    Cantrell JE, Phillips TM, Schein PS. Carcinoma-associated hemolytic-uremic syndrome: a complication of mitomycin-C chemotherapy. Clin Oncol 1985; 3: 723–734Google Scholar
  189. 189.
    Pavy MD, Wiley EL, Abeloff MD. Hemolytic-uremic syndrome associated with mitomycin therapy. Cancer Treat Rep 1982; 66: 457–61PubMedGoogle Scholar
  190. 190.
    Salmon SE. Nitrosoureas in multiple myeloma. Cancer Treat Rep 1976; 60: 789–94PubMedGoogle Scholar
  191. 191.
    Young RC, DeVita VT, Serpick AA. Treatment of advanced Hodgkins disease with 1,3-bis(2-chloroethyl)-1-nitrosourea BCNU. N Engl J Med 1971; 285: 475–9PubMedGoogle Scholar
  192. 192.
    Anderson T, DeVita VT, Young RC. BCNU (NSC-409963) in the treatment of advanced Hodgkins disease: its role in remission introduction and maintenance. Cancer Treat Rep 1976; 60: 761–7PubMedGoogle Scholar
  193. 193.
    Kanj SS, Sharara AL, Shpall EJ, et al. Myocardial ischemia associated with high dose carmustine infusion. Cancer 1991; 68: 1910–2PubMedGoogle Scholar
  194. 194.
    Henner WD, Peters WP, Eder JP, et al. Pharmacokinetics and immediate effects of high-dose carmustine in man. Cancer Treat Rep 1986; 70: 887–91Google Scholar
  195. 195.
    Ehrsson H, Hassan M, Ehrnebo M, et al. Busulfan pharmaco-kinetics. Clin Pharmacol Ther 1983; 34: 86–9PubMedGoogle Scholar
  196. 196.
    Santos GW, Tutschka PJ, Brookmeyer R, et al. Marrow transplantation for acute non-lymphocytic leukemia after treatment with busulfan and cyclophosphamide. N Engl J Med 1983; 309: 1347–53PubMedGoogle Scholar
  197. 197.
    Hartmann O, Benhamou E, Beaujean F, et al. High-dose busulfan and cyclophosphamide with autologous bone marrow transplantation support in advanced malignancies in children: a phase II study. J Clin Oncol 1986; 4: 1804–10PubMedGoogle Scholar
  198. 198.
    Myleran®. Physicians Desk Reference. Montvale (NJ): Medical Economics Company Inc., 1999: 1181–4Google Scholar
  199. 199.
    Terpstra W, De Maat CEM. Pericardial fibrosis following busulfan treatment. Neth J Med 1989; 35: 249–52PubMedGoogle Scholar
  200. 200.
    Weinberger A, Pinkhas J, Sandbank U, et al. Endocardial fibrosis following busulfan treatment. JAMA 1975; 231: 495PubMedGoogle Scholar
  201. 201.
    Litter WR, Kay JH, Hasleton PS, et al. Busulphan lung. Thorax 1969; 24: 639–55Google Scholar
  202. 202.
    Oliner H, Schwartz R, Kubio Jr F, et al. Interstitial pulmonary fibrosis following busulfan therapy. Am J Med 1961; 31: 134–9PubMedGoogle Scholar
  203. 203.
    Van Scott EJ, Kalmanson JD. Complete remission of mycosis fungoides lymphoma induced by topical nitrogen mustard (HN2). Cancer 1973; 32: 18–30PubMedGoogle Scholar
  204. 204.
    Nicholson WM, Beard ME, Crowther D. Combination chemotherapy in generalized Hodgkins disease. Br Med J 1970; 3: 7–10PubMedGoogle Scholar
  205. 205.
    Zackheim HS, Arnold JE, Farber BM. Topical therapy of psoriasis with mechlorethamine. Arch Dermatol 1972; 105: 702–6PubMedGoogle Scholar
  206. 206.
    Hartmann DW, Robinson WA, Mangalik A, et al. Unanticipated side effects of treatment with high dose mechlorethamine in patients with malignant melanoma. Cancer Treat Rep 1981; 65: 327–8PubMedGoogle Scholar
  207. 207.
    Hartmann DW, Robinson WA, Morton NJ, et al. High dose nitrogen mustard (HN2) with autologous nonfrozen bone marrow transplantation in advanced malignant melanoma. A phase I trial. Blut 1981; 42: 209–20PubMedGoogle Scholar
  208. 208.
    Allegra CJ, Grem JL. Antimetabolites. In: DeVita VT, Hellman S, Rosenberg SA, editors. Cancer: principles and practice of oncology. 5th edition. Philadelphia: Lippincott-Raven, 1997: 432–52Google Scholar
  209. 209.
    Labianca R, Beretta G, Clerici M, et al. Cardiotoxicity of 5-FU: A study of 1083 patients. Tumori 1982; 68: 505–10PubMedGoogle Scholar
  210. 210.
    Patel B, Kloner RA, Ensley J, et al. 5-Fluorouracil cardiotoxicity: left ventricular dysfunction and effect of coronary vasodilators. Am J Med Sci 1987; 294: 238–43PubMedGoogle Scholar
  211. 211.
    deForni M, Malet-Martino MC, Jaillais P, et al. Cardiotoxicity of high dose continuous infusion fluorouracil: a prospective clinical study. J Clin Oncol 1992; 10: 1795–801Google Scholar
  212. 212.
    Rezkalla S, Kloner RA, Ensley J, et al. Continuous ambulatory ECG monitoring during fluorouracil therapy: a prospective study. J Clin Oncol 1989; 7: 509–14PubMedGoogle Scholar
  213. 213.
    Gradishar WJ, Vokes EE. 5-Fluorouracil cardiotoxicity: a critical review. Ann Oncol 1991; 1: 409–14Google Scholar
  214. 214.
    Eskilsson J, Albertsson M, Mercke C. Adverse cardiac effects during induction chemotherapy treatment with cisplatin and 5-fluorouracil. Radiother Oncol 1988; 13: 41–6PubMedGoogle Scholar
  215. 215.
    Collins C, Weiden PL. Cardiotoxicity of 5-fluorouracil. Cancer Treat Rep 1987; 71: 733–6PubMedGoogle Scholar
  216. 216.
    Ensley JF, Patel B, Kolner R, et al. The clinical syndrome of 5-fluorouracil cardiotoxicity. Invest New Drugs 1989; 7: 101–9PubMedGoogle Scholar
  217. 217.
    Sanani S, Spaulding MB, Masud AR, et al. 5-FU cardiotoxicity. Cancer Treat Rep 1981; 65: 1123–5PubMedGoogle Scholar
  218. 218.
    Robben NC, Pippas AW, Moore JO. The syndrome of 5-fluorouracil cardiotoxicity. Cancer 1993; 71: 493–509PubMedGoogle Scholar
  219. 219.
    Pottage A, Holt S, Ludgate S, et al. Fluorouracil cardiotoxicity. Br Med J 1978; 1: 547PubMedGoogle Scholar
  220. 220.
    May D, Wandl U, Beher R, et al. Cardiac side effects of 5-fluorouracil. Deut Med Wochernschr 1990; 115: 618–21Google Scholar
  221. 221.
    Fajardo LF, Stewart JR. Pathogenesis of radiation-induced myocardial fibrosis. Lab Invest 1973; 29: 244–55PubMedGoogle Scholar
  222. 222.
    Lindsay E, Enterman C, Ellis EE, et al. Aortic atherosclerosis in the dog after localized aortic irradiation with electrons. Circ Res 1962; 10: 61–7PubMedGoogle Scholar
  223. 223.
    Lang-Stevenson D, Mikhailidis DP, Gillett DS. Cardiotoxicity of 5-fluorouracil. Lancet 1977; II: 406–7Google Scholar
  224. 224.
    Thyss A, Gaspard MH, Marsault R, et al. Very high endothelin plasma levels in patients with 5-FU induced vasoconstriction in isolated rabbit aortic rings [letter]. Ann Oncol 1992; 3: 88PubMedGoogle Scholar
  225. 225.
    Gradishar W, Vokes EE, Schilsky R, et al. Vascular events in patients receiving high dose infusional 5-fluorouracil based chemotherapy: the University of Chicago experience. Med Pediatr Oncol 1991; 19: 8–15PubMedGoogle Scholar
  226. 226.
    Kuzel T, Esyaraz B, Green D, et al. Thrombogenicity of intravenous 5-fluorouracil alone or in combination with cisplatin. Cancer 1990; 65: 885–9PubMedGoogle Scholar
  227. 227.
    Lemaire L, Malet-Martino MC, deForni M, et al. Cardiotoxicity of commercial 5-fluorouracil stems from the alkaline hydrolysis of the drug. Br J Cancer 1992; 66: 119–27PubMedGoogle Scholar
  228. 228.
    Lemaire L, de Forni M, Malet-Martino MC, et al. Conversion of fluorinated impurity(ies) contained in vials of fluorouracil (Roche) into highly cardiotoxic fluoroacetate [abstract]. Eur J Cancer 1991; 27: 326Google Scholar
  229. 229.
    Lemaire L, Malet-Martino MC, Longo S, et al. Fluoroacetaldehyde as cardiotoxic impurity in fluorouracil (Roche) [letter]. Lancet 1991; 337: 560PubMedGoogle Scholar
  230. 230.
    Malet-Martino MC, Lemaire L, de Forni M, et al. Impurity (ies) in vials of fluorouracil (Roche) is (are) converted in vivo into highly cardiotoxic fluoroacetate [abstract]. Proc Am Assoc Cancer Res 1991; 32: 2523Google Scholar
  231. 231.
    Pattison FLM, Peters RA. Monofluoro aliphatic comounds. Handbook of experimental pharmacology. Vol 20, Pt 1. New York (NY): Springer Verlag, 1966: 387–458Google Scholar
  232. 232.
    Eskilsson J, Albertsson M. Failure of preventing 5-fluorouracil cardiotoxicity by prophylactic treatment with verapamil. Acta Oncol 29: 1990: 1001–3Google Scholar
  233. 233.
    Schober C, Papageorgiou E, Harstrick A, et al. Cardiotoxicity of 5-fluorouracil in combination with folinic acid in patients with gastrointestinal cancer. Cancer 1993; 72: 2242–7PubMedGoogle Scholar
  234. 234.
    Oleksowicz L, Bruckner HW. Prophylaxis of 5-fluorouracil-induced coronary vasospasm with calcium channel blockers. Am J Med 1988; 85: 750–1PubMedGoogle Scholar
  235. 235.
    Willemze R, Zwaan FE, Colpin G, et al. High dose cytosine arabinoside in the management of refractory acute leukemia. Scan J Haematol 1982; 29: 141–6Google Scholar
  236. 236.
    Conrad ME. Cytarabine and cardiac failure. Am J Hematol 1992; 41:143–4Google Scholar
  237. 237.
    Andersson BS, Cogan BM, Keating MJ, et al. Subacute pulmonary failure complicating high-dose Ara-C in acute leukemia. Cancer 1985; 56: 2181–4PubMedGoogle Scholar
  238. 238.
    Haupt HM, Hutchins GM, Moore GW. Ara-C lung: non-cardiogenic pulmonary edema complicating cytosine arabinoside therapy of leukemia. Am J Med 1981; 70: 256–61PubMedGoogle Scholar
  239. 239.
    Donehower RC, Karp JE, Burke PJ. Pharmacology and toxicity of high-dose cytarabine by 72-hour continuous infusion. Cancer Treat Rep 1986; 70: 1059–65PubMedGoogle Scholar
  240. 240.
    Chiche D, Pico JL, Bernaudin JF, et al. Pulmonary edema and shock after high-dose aracytine-C for lymphoma: possible role of TNF-alpha and PAF. Eur Cytokine Netw 1993; 4: 147–51PubMedGoogle Scholar
  241. 241.
    Castleberry RP, Crist WM, Holbrook T, et al. The cytosine arabinoside syndrome. Med Pediatr Oncol 1981; 9: 257PubMedGoogle Scholar
  242. 242.
    Vaickus L, Letendre L. Pericarditis induced by high-dose cytarabine therapy. Arch Intern Med 1984; 144: 1868–9PubMedGoogle Scholar
  243. 243.
    Reykdal S, Sham R, Kouides P. Cytarabine-induced pericarditis: a case report and review of the literature of the cardio-pulmonary complications of cytarabine therapy. Leuk Res 1995; 19(2): 141–4PubMedGoogle Scholar
  244. 244.
    Williams SF, Larson RA. Hypersensitivity reaction to high-dose cytarabine. Br J Haematol 1989; 73: 274PubMedGoogle Scholar
  245. 245.
    Rowinsky EK, Donehower RC. Drug therapy: paclitaxel (Taxol). N Engl J Med 1996; 332: 1004–14Google Scholar
  246. 246.
    Rowinsky EK, Cazenare LA, Donehower RC. Taxol: a novel investigational antineoplastic agent. J Natl Cancer Inst 1990; 82: 1247–59PubMedGoogle Scholar
  247. 247.
    Weiss RB, Donehower RC, Wiernik PH, et al. Hypersensitivity reactions from taxol. J Clin Oncol 1990; 8: 1263–8PubMedGoogle Scholar
  248. 248.
    Rowinsky EK, McGuire WP, Guarnieri T, et al. Cardiac disturbances during the administration of taxol. J Clin Oncol 1991; 9: 1704–12PubMedGoogle Scholar
  249. 249.
    Arbuck SG, Strauss H, Rowinsky E, et al. A reassessment of cardiac toxicity associated with taxol. J Natl Cancer Inst Mono 1993; 15: 117–30Google Scholar
  250. 250.
    McGuire WP, Rowinsky EK, Rosenshein NB, et al. Taxol: a unique antineoplastic agent with significant activity in advanced ovarian epithelial neoplasms. Ann Intern Med 1989; 111: 273–9PubMedGoogle Scholar
  251. 251.
    Rowinsky EK, Gilbert MR, McGuire WP, et al. Sequences of taxol and cisplatin: a phase I and pharmacologic study. J Clin Oncol 1991; 9: 1692–703PubMedGoogle Scholar
  252. 252.
    Lorenz W, Perlmann HJ, Schmall A, et al. Histamine release in dogs by Cremophor E-EL and its derivatives. Agents Action 1977; 7: 63–7Google Scholar
  253. 253.
    Bristow MR, Ginsburg R, Harrison DC. Histamine and the human heart: the other receptor system. Am J Cardiol 1982; 49: 249–51PubMedGoogle Scholar
  254. 254.
    Bristow MR, Minobe WA, Billingham ME, et al. Anthracycline associated cardiac and renal damage in rabbits. Evidence for mediation by vasoactive substances. Lab Invest 1981; 45: 157–68PubMedGoogle Scholar
  255. 255.
    Bristow MR, Sageman WS, Scott RH, et al. Acute and chronic cardiovascular effects of doxorubicin in the dog: the cardiovascular pharmacology of drug-induced histamine release. J Cardiovasc Pharmacol 1980; 2: 487–515PubMedGoogle Scholar
  256. 256.
    Levi R, Zavecz JH. Acceleration of idioventricular rhythms by histamine in the guinea pig heart: mediation by H2 receptors. Cir Res 1979; 44: 847–55Google Scholar
  257. 257.
    Levi R. Effects of exogenous and immunobiologically released histamine on the isolated heart: a quantitative comparison. J Pharmacol Exp Ther 1972; 182: 227–45PubMedGoogle Scholar
  258. 258.
    Hageman GR, Urthaler F, Isobe JH, et al. Chronotropic and dromotropic effects of histamine on the canine heart. Chest 1979; 75: 597–604PubMedGoogle Scholar
  259. 259.
    Ginsburg R, Bristow MR, Kantrowitz N, et al. Histamine provocation of clinical coronary artery spasm: implications concerning pathogenesis of variant angina pectoris. Am Heart J 1981; 102: 819–25PubMedGoogle Scholar
  260. 260.
    Dukes MN. Myelers side effects of drugs. 11th ed. New York: Elsevier, 1991Google Scholar
  261. 261.
    Fainstein V, Body GP. Cardiorespiratory toxicity due to miconazole. Ann Intern Med 1980; 93: 432–3PubMedGoogle Scholar
  262. 262.
    Annual report to the FDA, VM-26 (NSC 122819), Baltimore (MD); 1991Google Scholar
  263. 263.
    Sandimmune®. Physicians Desk Reference. Montvale (NJ): Medical Economics Company Inc., 1999; 2079–83Google Scholar
  264. 264.
    Cimetidine. Physicians Desk Reference. Montvale (NJ): Medical Economics Company Inc. 1999; 3094–8Google Scholar
  265. 265.
    Zantac®. Physicians Desk Reference. Montvale (NJ): Medical Economics Company Inc. 1999; 1260–2Google Scholar
  266. 266.
    Bryan-Brown T. The pharmacological actions of Taxine. Q J Pharmacol 1932; 5: 205–19Google Scholar
  267. 267.
    Burke MJ, Siegel BS, Davidow B. Consequence of yew (Taxus) needle ingestion. NY State J Med 1979; 79: 1576–7Google Scholar
  268. 268.
    Schulte T. Lethal intoxication with the leaves of the yew tree (Taxus baccata). Arch Toxicol 1975; 34: 153–8PubMedGoogle Scholar
  269. 269.
    Veatch JK, Reid FM, Kennedy GA. Differentiating yew poisoning from other toxicioses. Vet Med 1988; 81: 298–300Google Scholar
  270. 270.
    Tekol Y. Negative chronotropic and atrioventricular blocking effects of taxine on isolated frog heart and its acute toxicity in mice. Plant Medica 1985; 5: 357–60Google Scholar
  271. 271.
    Gianni L, Munzone E, Capri G, et al. Paclitaxel by 3-hour infusion in combination with bolus doxorubicin in women with untreated metastatic breast cancer: high antitumor efficacy and cardiac effects in a dose-finding and sequence finding study. J Clin Oncol 1995; 13: 2688–99PubMedGoogle Scholar
  272. 272.
    Rowinsky EK, Donehower RC. Antimicrotubule agents. In: DeVita Jr VT, Hellman S, Rosenberg SA, editors. Cancer: principles and practice of oncology. Philadelphia: Lippincott-Raven, 1997: 467–83Google Scholar
  273. 273.
    Hirvonen HE, Salmi TT, Heinon E, et al. Vincristine treatment of acute lymphoblastic leukemia induces transient autonomic cardioneuropathy. Cancer 1989; 64: 801–5PubMedGoogle Scholar
  274. 274.
    Roca E, Bruera E, Politi PM, et al. Vinca alkaloid-induced cardiovascular autonomic neuropathy. Cancer Treat Rep 1985; 69: 149–51PubMedGoogle Scholar
  275. 275.
    Cargill RI, Boyter AC, Lipworth BJ. Reversible myocardial ischaemia following vincristine containing chemotherapy. Resp Med 1994; 88: 709–10Google Scholar
  276. 276.
    Somers G, Abramov M, Witter M, et al. Myocardial infarction: a complication of vincristine treatment [letter]? Lancet 1976; 690Google Scholar
  277. 277.
    Mandel EM, Lewinski U, Djaldetti M. Vincristine-induced myocardial infarction. Cancer 1975; 36: 1979–82PubMedGoogle Scholar
  278. 278.
    Samuels BL, Vogelzang NJ, Kennedy BJ. Severe vascular toxicity associated with vinblastine, bleomycin and cisplatin chemotherapy. Cancer Chemother Pharmacol 1987; 19: 253–6PubMedGoogle Scholar
  279. 279.
    Subar M, Muggia FM. Apparent myocardial ischemia associated with vinblastine administration. Cancer Treat Rep 1986; 70: 690–1PubMedGoogle Scholar
  280. 280.
    Vogelzang NJ, Frenning DH, Kennedy BJ. Coronary artery disease after treatment with bleomycin and vinblastine. Cancer Treat Rep 1980; 64: 1159–60PubMedGoogle Scholar
  281. 281.
    Blijham GH, Fiolet HH, van Deijk WA, et al. Angina pectoris associated with infusion of 5-FU and vindesine. Cancer Treat Rep 1986; 70: 314–5PubMedGoogle Scholar
  282. 282.
    Yancy RS, Talpaz M. Vindesine associated angina and ECG changes. Cancer Treat Rep 1982; 66: 587–9Google Scholar
  283. 283.
    Bedikian AY, Valdivieso M, Maroun J, et al. Evaluation of vindesine and MER in colorectal cancer. Cancer 1980; 46: 463–7PubMedGoogle Scholar
  284. 284.
    Bergeron A, Raffy O, Vannetzel JM. Myocardial ischemia and infarction associated with vinorelbine. J Clin Oncol 1995; 13: 531–2PubMedGoogle Scholar
  285. 285.
    Roberts WC, Clancy DL, DeVita VT. Heart in malignant lymphoma, Hodgkins disease, lymphosarcoma, and myocardial fungoides. Am J Cardiol 1968; 22: 85–107PubMedGoogle Scholar
  286. 286.
    Stewart CF, Ratain MJ. Topoisomerase interactive agents. In: DeVita Jr VT, Hellman S, Rosenberg SA, editors. Cancer: principles and practice of oncology. Philadelphia: Lippincott-Raven, 1997: 452–67Google Scholar
  287. 287.
    Schwarzer S, Eber B, Greinix H, et al. Non-Q-wave myocardial infarction associated with bleomycin and etoposide chemotherapy. Eur Heart J 1991; 12: 748–50PubMedGoogle Scholar
  288. 288.
    VePesid®. Physicians Desk Reference. Montvale (NJ): Medical Economics Company Inc. 1999; 804–6Google Scholar
  289. 289.
    Rozencweig M, Von Hoff DD, Henney JE, et al. VM-26 and VP-16-213: a comparative analysis. Cancer 1977; 40: 334–42PubMedGoogle Scholar
  290. 290.
    Cohen MH, Broder LE, Fossieck BE, et al. Phase II clinical trial of weekly administration of VP-16-213 in small-cell bronchogenic carcinoma. Cancer Treat Rep 1977; 61: 489–90PubMedGoogle Scholar
  291. 291.
    Aisner J, Whitacre M, Van Echo DA, et al. Combination chemotherapy for small-cell carcinoma of the lung: continuous verses alternating non-cross-resistant combinations. Cancer Treat Rep 1982; 66: 221–30PubMedGoogle Scholar
  292. 292.
    Airey CL, Dodwell DJ, Joffe JK, et al. Etoposide-related myocardial infarction. Clin Oncol 1995; 7: 135Google Scholar
  293. 293.
    Schechter JP, Jones SE, Jackson RA. Myocardial infarction in a 27-year-old woman: possible complication of treatment with VP 16-213 (NSC-141540), mediastinal irradiation, or both. Cancer Chemother Rep 1975; 59: 887–8Google Scholar
  294. 294.
    Vumon®. Physicians Desk Reference. Montvale (NJ): Medical Economics Company Inc. 1999; 810–2Google Scholar
  295. 295.
    O’Dwyer PJ, King SA, Fortner CL, Leyland-Jones B. Hypersensitivity reactions to teniposide (VM-26): an analysis. J Clin Oncol 1986; 4: 1262–9PubMedGoogle Scholar
  296. 296.
    Grove WR, Fortner CL, Wiernik PH. Review of amsacrine, an investigational antineoplastic agent. Clin Pharm 1982; 1: 320–6PubMedGoogle Scholar
  297. 297.
    Weiss RB, Grille-Lopez AJ, Marsoni S, et al. Amsacrine-associated cardiotoxicity: an analysis of 82 cases. J Clin Oncol 1986; 4: 918–28PubMedGoogle Scholar
  298. 298.
    Ratanatharathorn V, Drelichman A, Sexon-Porte M, et al. Phase II evaluation of 4-(9-aciridinylamino) methanesulfon-manisidide (AMSA) in patients with advanced head and neck cancers. Am J Clin Oncol 1982; 5: 29–32PubMedGoogle Scholar
  299. 299.
    Ettinger DS, Day R, Ferraro JA, et al. A randomized phase II study of m-AMSA (NSC 249992) and neocarzinostatin (NSC 157365) in non-small bronchogenic carcinoma. An Eastern Cooperative Group Study. Am J Clin Oncol 1983; 6: 167–70PubMedGoogle Scholar
  300. 300.
    Legha SS, Blumenschein GR, Buzdar AU, et al. Phase II study of 4-(9-aciridinylamino) methanesulfon-m-anisidide (AMSA) in metastatic breast cancer. Cancer Treat Rep 1979; 63: 1961–4PubMedGoogle Scholar
  301. 301.
    Schneider RJ, Woodcock TM, Yagoda A. Phase II trial of 4-(9-aciridinylamino) methanesulfon-m-anisidide (AMSA) in patients with metastatic hypernephroma. Cancer Treat Rep 1980; 64: 183–5PubMedGoogle Scholar
  302. 302.
    Legha SS, Hall SW, Powell KC, et al. Phase II study of 4-(9-aciridinylamino) methanesulfon-m-anisidide (AMSA) in metastatic melanoma. Cancer Clin Trials 1980; 3: 111–4PubMedGoogle Scholar
  303. 303.
    Bukowski RM, Leichman LP, Rivkin SE. Phase II trial of m-AMSA in gallbladder and cholangiocarcinoma: a Southwest Oncology Group Study. Eur J Cancer Clin Oncol 1983; 19: 721–3PubMedGoogle Scholar
  304. 304.
    De Jager R, Siegenthaler P, Cavalli F, et al. Phase II study of amsacrine in solid tumors: a report of the EORTC Early Clinical Trial Group. Eur J Cancer Clin Oncol 1983; 19: 289–93PubMedGoogle Scholar
  305. 305.
    Dupont JC, Garay GE, Scaglione C, et al. A phase II trial of m-AMSA in acute leukemia [abstract]. Proc Am Soc Clin Oncol 1981; 22: 477Google Scholar
  306. 306.
    Land V, Civin C, Regab A, et al. Efficacy and toxicity of 4’-(9-acridinylamino) methanesulfon-m-anisidide (AMSA) in advanced childhood leukemia [abstract]. Proc Am Soc Clin Oncol 1981; 22: 403Google Scholar
  307. 307.
    Lessner H, Kaplan R. m-AMSA treatment of advanced colorectal, pancreatic and gastric carcinoma [abstract]. Proc Am Soc Clin Oncol 1981; 22: 454Google Scholar
  308. 308.
    Von Hoff DD, Elson D, Polk G, et al. Acute ventricular fibrillation and death during infusion of 4’-(9-acridinylamino) methanesulfon-m-ansidide (AMSA). Cancer Treat Rep 1980; 64: 356–7Google Scholar
  309. 309.
    Falkson G. Multiple ventricular extrasystoles following administration of 4’-(9-aciridinylamino) methanesulfon-m-anisidide (AMSA). Cancer Treat Rep 1980; 64: 356–8Google Scholar
  310. 310.
    Steinherz L, Mangiacasale D, Steinherz P. et al. Echocardiographic and ECG abnormalities in pediatric patients receiving 4-(9-acridinylamino)-methanesulfon-m-anisidide (AMSA) [abstract]. Proc Am Assoc Cancer Res 1980; 21: 143Google Scholar
  311. 311.
    Riela AR, Kimball JC, Patterson RB. Cardiac arrhythmia associated with AMSA in a child. A Southwest Oncology Group Study. Cancer Treat Rep 1981; 65: 1121–3PubMedGoogle Scholar
  312. 312.
    Foldes JA, Yagil Y, Kornberg A. Ventricular fibrillation, hypokalemia, and AMSA therapy. Ann Intern Med 1982; 96: 121–2PubMedGoogle Scholar
  313. 313.
    Steinherz LJ, Steinherz PG, Mangiacasale D, et al. Cardiac abnormalities after AMSA administration. Cancer Treat Rep 1982; 66: 483–8PubMedGoogle Scholar
  314. 314.
    Miller CF, Rajdev N. Acute ECG changes associated with AMSA treatment. Case reports. Cancer Treat Rep 1982; 66: 1679–80Google Scholar
  315. 315.
    Vorobiof DA, Iturralde M, Falkson G. Amsacrine cardiotoxicity: assessment of ventricular function by radionuclide angiography. Cancer Treat Rep 1983; 67(12): 1115–7PubMedGoogle Scholar
  316. 316.
    Legha SS, Gutterman JU, Hall SW, et al. Phase I clinical investigation of 4-(9-acridinylamino)-methanesulfon-m-anisidide (NSC 249992), a new acridine derivative. Cancer Res 1978; 38: 3712–6PubMedGoogle Scholar
  317. 317.
    Legha SS, Latreille J, McCredie KB, et al. Neurologic and cardiac rhythm abnormalities associated with 4’-(9-aciridinylamino) methanesulfon-m-anisidide (AMSA) therapy. Cancer Treat Rep 1979; 63: 2001–3PubMedGoogle Scholar
  318. 318.
    Piro LD, Carrera CJ, Carson DA, et al. Lasting remission in hairy cell leukemia induced by a single infusion of 2-chlorodeoxyadenosine. N Engl J Med 1990; 322: 1117–21PubMedGoogle Scholar
  319. 319.
    Estey EH, Kurzrock R, Kantarjian HM, et al. Treatment of hairy cell leukemia with 2-chlorodeoxyadenosine (2-CdA). Blood 1992; 79: 882–7PubMedGoogle Scholar
  320. 320.
    Seymour JF, Kurzrock R, Freireich EJ, et al. 2-Chlorodeoxyadenosine induces durable remission and prolonged suppression of CD4+ lymphocyte counts in patients with hairy cell leukemia. Blood 1994; 83: 2906–11PubMedGoogle Scholar
  321. 321.
    Koczwara B, Spangenthal E, Bernstein SH. The development of congestive cardiac failure in a patient with hairy cell leukemia treated with 2-chlorodeoxyadenosine. Leuk Lymphoma 1997; 26: 413–5PubMedGoogle Scholar
  322. 322.
    Rosenthal RA, Lowenstein JM. Inhibition of phosphorylation of troponin in rat heart by adenosine and 5-chloro-5-deoxyadenosine. Biochem Pharmacol 1991; 42: 685–92PubMedGoogle Scholar
  323. 323.
    Rockoff JB, Dobson Jr JG. Inhibition by adenosine of catecholamine induced increase in rat atrial contractility. Am J Physiol 1980; 239: H365–70PubMedGoogle Scholar
  324. 324.
    Cheson BD. Miscellaneous chemotherapeutic agents. In: DeVita Jr VT, Hellman S, Rosenberg SA, editors. Cancer: principles and practice of oncology. Philadelphia: Lippincott-Raven, 1997: 490–8Google Scholar
  325. 325.
    Jones B, Holland JF, Glidewell O, et al. Optimal use of Lasparaginase (NSC-109229) in acute lymphocytic leukemia. Med Pediatr Oncol 1977; 3: 387–400PubMedGoogle Scholar
  326. 326.
    Oettgen HF, Old LJ, Boyse EA, et al. Therapeutic effect of L-asparaginase on asparagine-dependent neoplasms: laboratory and clinical studies [abstract]. J Clin Invest 1968; 47: 4aGoogle Scholar
  327. 327.
    Ohnuma T, Holland JF, Freeman A, et al. Biochemical and pharmacological studies with asparaginase in man. Cancer Res 1970; 30: 2297–305PubMedGoogle Scholar
  328. 328.
    Cairo MS, Lazarus K, Gilmore RL, et al. Intracranial hemorrhage and focal seizures secondary to use of L-asparaginase during induction therapy of acute lymphocytic leukemia. J Pediatr 1980; 97: 829–33PubMedGoogle Scholar
  329. 329.
    Conard J, Cazenave B, Maury J, et al. L-asparaginase, antithrombin III, and thrombosis [letter]. Lancet 1980; I: 1091Google Scholar
  330. 330.
    Fragassi G, Pastore MR, Vicari A, et al. Myocardial infarction in a patient with acute lymphoblastic leukemia during L-asparaginase therapy. Am J Hematol 1995; 48: 136–7Google Scholar
  331. 331.
    Kraut EH, Grever MR, Bouroncle BA. Long-term follow-up of patients with hairy cell leukemia after treatment with 2deoxycoformycin. Blood 1994; 84: 4061–3PubMedGoogle Scholar
  332. 332.
    Grever M, Kopecky K, Foucar MK, et al. A randomized comparison of pentostatin versus alpha-interferon in previously untreated patients with hairy cell leukemia: an intergroup study. J Clin Oncol 1995; 13: 974–82PubMedGoogle Scholar
  333. 333.
    Grem JL, King SA, Chun HG, et al. Cardiac complications observed in elderly patients following 2-deoxycoformycin therapy. Am J Hematol 1991; 38: 245–7PubMedGoogle Scholar
  334. 334.
    Nipent®. Physicians Desk Reference. Montvale (NJ): Medical Economics Company Inc., 1999; 3133–6Google Scholar
  335. 335.
    Gryn J, Gordon R, Bapat A, et al. Pentostatin increases the acute toxicity of high dose cyclophosphamide. Bone Marrow Transplant 1993; 12: 217–20PubMedGoogle Scholar
  336. 336.
    Dhasmana JP, Digerness SB, Geckle JM, et al. Effect of adenosine deaminase inhibitors on the hearts functional and biochemical recovery from ischemia: a study utilizing the isolated rat heart adapted to 31P nuclear magnetic resonance. J Cardiovasc Pharmacol 1983; 5: 1040–7PubMedGoogle Scholar
  337. 337.
    Zoref-Shani E, Shainberg A, Sperling O. Pathways of adenine nucleotide catabolism in primary rat muscle cultures. Biochim Biophys Acta 1987; 962: 287–95Google Scholar
  338. 338.
    Warrell Jr RP. Differentiation agents. In: DeVita Jr VT, Hellman S, Rosenberg SA, editors. Cancer: principles and practice of oncology. Philadelphia (PA): Lippincott-Raven, 1997: 483–90Google Scholar
  339. 339.
    Vesanoid®. Physicians Desk Reference. Montvale (NJ): Medical Economics Company Inc., 1999: 2726–8 ((Check this layout with Rosie))Google Scholar
  340. 340.
    Frankel SR, Eardley A, Heller G, et al. All-transretinoic acid for acute promyelocytic leukemia. Ann Intern Med 1994; 120: 278–86PubMedGoogle Scholar
  341. 341.
    Escudier SM, Kantarjian HM, Estey EH. Thrombosis in patients with acute promyelocytic leukemia treated with and without all-trans retinoic acid. Leuk Lymphoma 1996; 20: 435–9PubMedGoogle Scholar

Copyright information

© Adis International Limited 2000

Authors and Affiliations

  1. 1.College of Pharmacy, Ohio State University and Wexner Institute for Paediatric Research, Children’s HospitalColumbusUSA

Personalised recommendations